Lexeo Therapeutics Announces Acquisition of Mantle Therapeutics

What Happened
Lexeo Therapeutics, Inc. announced it completed its merger with Mantle Therapeutics (Merger Agreement dated Sept. 16, 2026), as reported in an 8-K filed Sept. 29, 2026. At the closing (the “Effective Time”), each outstanding Mantle share (other than certain excluded shares) was converted into the right to receive aggregate upfront consideration consisting of $5,300,000 in cash (subject to adjustments) and $3,000,000 in Lexeo common stock. Mantle restricted stock vested and was cancelled for the same consideration; outstanding SAFEs were cancelled for their applicable liquidity-event consideration; and convertible notes were cancelled upon payment of their payoff amounts.

Key Details

• Upfront consideration at closing: $5,300,000 cash + $3,000,000 in Lexeo common stock (stock issued unregistered under Section 4(a)(2)/Reg D).
• Additional contingent payments: one-time additional cash payment of $1,000,000 (conditional) and up to $12,000,000 in milestone payments over a 12‑year term (some cash, some stock valued using a 30‑day trailing VWAP).
• Merger Agreement dated Sept. 16, 2026; related merger agreement exhibit incorporated by reference in the filing.
• Lexeo is not required to guarantee milestone achievement and is only obligated to use “commercially reasonable efforts” for development/commercialization per the agreement.

Why It Matters
This transaction adds Mantle’s assets and product candidates to Lexeo’s portfolio, with a modest upfront cash outlay ($5.3M) and $3.0M issued in stock, which may cause dilution. The contingent $1M and up to $12M in milestone payments create potential future cash or equity obligations but are not guaranteed. Investors should note the securities issued were done in a private-exemption (not registered), and the agreement does not commit Lexeo to specific resource levels beyond commercially reasonable efforts.